Publications by authors named "D Mohty"
ESC Heart Fail
October 2024
Article Synopsis
- This study evaluates global differences in the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF) through an international survey of 1459 physicians, including both cardiologists and non-cardiologists.
- The survey revealed significant regional variations in HFpEF management, such as differences in natriuretic peptide usage and echocardiographic practices, with cardiologists managing the majority of HFpEF patients.
- The preferred treatment methods varied by region, with sodium glucose co-transporter-2 inhibitors (SGLT2i) being the most favored first-line treatment, though availability of these drugs differs significantly across locations.
ESC Heart Fail
December 2024
Article Synopsis
- The study focuses on cardiac amyloidosis (CA), a serious disease that is often overlooked, particularly in the Middle East, and aims to assess its prevalence and characteristics in a high-risk group in Saudi Arabia.
- It was a retrospective study conducted on heart failure patients at a hospital in Riyadh, using specific "red flags" like carpal tunnel syndrome and echocardiographic signs to identify those needing screening for CA.
- Out of 177 patients screened, 11.9% were diagnosed with transthyretin amyloid CA and 7.3% with light chain CA, noting that those with positive accompanying scans tended to be older.
Curr Probl Cardiol
December 2024
Article Synopsis
- A survey was conducted among physicians globally to evaluate the real-world practices for diagnosing and treating heart failure with preserved ejection fraction (HFpEF), highlighting a knowledge gap in clinical implementation.
- 1,460 physicians from 95 countries participated, primarily cardiologists, with most using a 50% ejection fraction cut-off for HFpEF diagnosis; however, only 47.2% utilized formal diagnostic scores.
- The results showed that while natriuretic peptides were commonly used (87.4%), SGLT2 inhibitors led as the preferred first treatment (54.4%), indicating a need for better education on HFpEF management.
Eur J Heart Fail
August 2024
Article Synopsis
- * A global survey conducted in 2023 revealed that non-cardiologists and cardiologists were less likely than heart failure specialists to utilize certain diagnostic tools and parameters like natriuretic peptides and specific echocardiographic techniques for diagnosing HFpEF.
- * While SGLT2 inhibitors and diuretics were commonly preferred medications across specialties, there was a notable variation in the selected first-choice drug for HFpEF, with heart failure specialists favoring SGLT2 inhibitors more than cardiologists
